Effects of Zhipo Liujunzi Decoction combined with sequential treatment on T lymphocyte subsets in patients with middle or advanced stage gastric cancer

Objective To analyze effects of Zhipo Liujunzi Decoction combined with sequential treatment on T lymphocyte subsets in patients with middle or advanced stage gastric cancer. Methods A total of 112 patients with middle or advanced gastric cancer hospitalized in our hospital were selected, and were divided into control group(n=56)and study group(n=56)according to random number table method. The control group was given sequential treatment, while the control group was treated with Zhipo Liujunzi Decoction combined with sequential treatment, and the clinical efficacy, serum tumor markers, T lymphocyte subgroup factors, and incidence of toxic and side effects were compared between the two groups. Results The total clinical effective rate in the experimental group was significantly higher than that in the control group(89.29% vs. 64.29%, P<0.05). After 3 courses of treatment, the levels of CD3⁺, CD4⁺, and CD4⁺ /CD8⁺ in the experimental group were significantly higher than those of the control group(P<0.05). The incidence of toxic side effects in the experimental group was significantly lower than the control group(P<0.05). The levels of serum carbohydrate antigen-724(CA-724), carcinoembryonic antigen(CEA), carbohydrate antigen-199(CA-199)in the experimental group were significantly lower than that of the control group after 3 courses of treatment(P<0.05). Conclusion Zhipo Liujunzi Decoction combined with sequential treatment can effectively inhibit the growth of tumor lesions, improve immune function, suppress serum tumor markers, and reduce the incidence of toxic and side effects in patients with middle or advanced stage gastric cancer.